W. L. Gore & Associates, Inc. (Gore) will highlight data gleaned from its Global Registry for Endovascular Aortic Treatment (GREAT) Study at the 45th Annual Symposium on Vascular and Endovascular Issues, VEITHsymposium in New York. The company is featuring the data in multiple presentations facilitated by lead investigators. GREAT is the largest industry-sponsored registry of aortic stent grafts with enrollment and follow-up data from over 100 sites across 13 countries.
We launched this registry in 2010 to evaluate and better understand how our family of aortic devices perform in real-world applications, and as a reflection of our continued commitment to advancing patient care in the treatment of aortic disease, said Eric Zacharias, Vascular Business Leader. The GREAT study draws from a pool of 5,000 patients who received one or more of the GORE EXCLUDER AAA Endoprostheses, GORE EXCLUDER Iliac Branch Endoprostheses, or Conformable GORE TAG Thoracic Endoprostheses. We are excited to share some of the conclusions and better inform our product offerings.
GREAT had broad inclusion criteria with minimal exclusion criteria to more accurately reflect real world clinical practice. Treatment results will be tracked for 10 years. This follow-up has and will continue to provide valuable insights into the long-term durability and behavior of Gore aortic endografts.
Traditionally, the industry has captured and shared data on migration, endoleak rates, rupture, conversions, and a few other data points, said Ross Milner, Professor of Surgery and Co-Director of the Center for Aortic Diseases at the University of Chicago Medical Center and National Co-Principal Investigator for GREAT in the US. In contrast, the GREAT investigators have been able to query the data to get insights into previously unanswered, rarely asked, or often unexplored areas of treatment. Our lunch symposium will explore a few of those topics.
Panel discussions on GREAT and the resulting observations will take place in the Main Pavilion, Mercury Ballroom, starting 12 p.m. EST Friday, November 16. The discussion will include the comprehensive portfolio of aortic products.
- Friday, Nov. 16: GREAT aortic endografting questions: What does the data reveal?
Pierre Galvagni Silveira, MD, Florianopolis, Brazil Andrew Holden, MD, Auckland, New Zealand Santi Trimarchi, MD, Milan, Italy
- The GREAT update: A review of one of the largest clinical registries for abdominal and thoracic aortic devices Beth Tohill, PhD, Flagstaff, Arizona
- Acute and chronic Type B aortic dissections: Exploring the nuances behind the data Dennis Gable, MD, Dallas, Texas
- Noncylindrical neck morphology: Incidence, effects, and risk of reintervention William Shutze, MD, Dallas, Texas
- Performance in the narrow distal aorta: Findings and implications Ross Milner, MD, Chicago
In addition to GREAT Registry discussions, Gore Medical will be hosting daily educational events at VEITHsymposium 2018, see full agenda here.
For more information on Gore aortic portfolio of products, visit www.goremedical.com/aortic.
Now in its 45th year, VEITHsymposium provides vascular surgeons, interventional radiologists, interventional cardiologists and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease. The 5- day event features rapid-fire presentations from world renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques.
Medical Products Division
Gore engineers devices that treat a range of cardiovascular and other health conditions. With more than 40 million medical devices implanted over the course of more than 40 years, Gore builds on its legacy of improving patient outcomes through research, education and quality initiatives. Product performance, ease of use and quality of service provide sustainable cost savings for physicians, hospitals and insurers. Gore is joined in service with clinicians and through this collaboration we are improving lives. www.goremedical.com
W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Founded in 1958, Gore has built a reputation for solving complex technical challenges in the most demanding environments from revolutionizing the outerwear industry with GORE-TEX fabric to creating medical devices that improve and save lives to enabling new levels of performance in the aerospace, pharmaceutical and mobile electronics markets, among other industries. The company is also known for its strong, team-oriented culture and global recognition from the Great Place to Work Institute. Headquartered in Newark, Del., Gore employs 9,500 Associates and generates annual revenues of $3.5 billion. www.gore.com
Products listed may not be available in all markets.
GORE, GORE-TEX, EXCLUDER, and TAG are trademarks of W. L. Gore & Associates. AX1499-EN1 OCTOBER 2018
Patients should consult with their physicians for information on the risk and uses associated with referenced devices or procedures. Physicians should refer to the Instructions for Use for the approved indications, contraindications, and information regarding instructions, warnings, and adverse reactions.
For complete indications and other important safety information for Gore commercial products referenced herein, refer to the applicable Instructions for Use (IFU).
Communication for Gore Medical
Liz DeForest, 212-584-5477